dipyridamole has been researched along with Bone Diseases, Metabolic in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaya, B | 1 |
| Altun, E | 1 |
| Paydas, S | 1 |
| Balal, M | 1 |
1 other study available for dipyridamole and Bone Diseases, Metabolic
| Article | Year |
|---|---|
The efficacy of dipyridamole in the treatment of hypophosphatemia- hypocalcemia for hungry bone syndrome in a hemodialysis patient.
Topics: Adult; Bone Diseases, Metabolic; Dipyridamole; Female; Humans; Hyperparathyroidism, Secondary; Hypoc | 2015 |